SLC5A2 and diabetes mellitus: The researchers have attempted to use various methods to treat diabetic sarcopenia (diabetes-induced skeletal muscle atrophy), such as resveratrol (Wang et al., 2018), exosomes derived from mesenchymal matrix cells (Song et al., 2023), SGLT2 inhibitors (Bamba et al., 2022), as well as a series of anti-inflammatory drugs such as IL-1 inhibitors, aspirin, and BMP-7 (Aluganti Narasimhulu and Singla, 2021; Ji et al., 2022).